Stay updated on Nintedanib for Progressive Fibrosing ILD Clinical Trial

Sign up to get notified when there's something new on the Nintedanib for Progressive Fibrosing ILD Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Nintedanib for Progressive Fibrosing ILD Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T23:36:01.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a potential update in the efficacy and safety evaluation of Nintedanib over 52 weeks in patients with Progressive Fibrosing Interstitial Lung Disease (PF-ILD). This change may reflect new findings or developments in the study regarding the treatment options for patients with PF-ILD.
    Difference
    0.1%
    Check dated 2024-06-06T14:50:42.000Z thumbnail image
  7. Check
    24 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for study participants, specifying the need for written informed consent and various health conditions and prior treatments required for inclusion. This change provides more specific information about the requirements for participants in the clinical study.
    Difference
    33%
    Check dated 2024-05-22T21:37:09.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.5%
    Check dated 2024-04-30T22:53:05.000Z thumbnail image

Stay in the know with updates to Nintedanib for Progressive Fibrosing ILD Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Nintedanib for Progressive Fibrosing ILD Clinical Trial page.